News about rights and multinationals
New chip releases large AI models from the cloud and runs them at low power in devices enabling full conversational dialog and complex AI inference inexpensively and at low power.
…
MUNICH – November 21, 2022 – (Newswire.com)
neurocare group AG (“neuroca…
State-of-the-art system of neural networks and machine learning models that transforms non-numeric healthcare provider voice responses at scale into measurable insights.
…
ANKARA, Turkey – November 20, 2022 – (Newswire.com)
Digital health start-up H2o therapeutics received 510(k) marketing clearance from the U.S. Food and Drug Administration for its prescription mobile app Parky for monitoring Parkinson’s Disease. Parky App monitors symptoms such as tremors and dyskinesia in real-time via the use of the Apple Watch. It is a tool for sharing meaningful and reliable data between patients and medical professionals regarding the course of the disease.
The app leverages the Movement Disorder API, a tool developed by Apple. The API was validated in a study of 343 participants, including longitudinal tracking of 225 participants for up to six months and used the clinical gold standard (MDS-UPDRS) as a reference. Details of the study were published in Science Translational Medicine last year.
10 million patients worldwide live with Parkinson’s Disease, the fastest-growing neurological disorder. Healthcare professionals in this area need reliable feedback and data for optimized treatment plans. Parky App helps medical professionals to develop a clinical profile of the patient while outside of the clinic. The Parky App strengthens the possibility of data-driven, tailored treatment procedures and bridges the gap between real-life and in-clinic settings.
“As a woman-founded, non VC-backed company based in Turkey, receiving our first 510(k) clearance is a huge milestone for us. We believe Parky will bring great value to the Parkinson’s Disease community as an easily scalable and data-driven product,” Yagmur Selin Gulmus, the founder of h2o therapeutics, said in a statement. The company has 2 more digital therapeutics products in the pipeline based on wearable devices and FDA submissions are planned to be completed in 2023.
h2o therapeutics is developing digital therapeutics with a focus on mobile technologies, Augmented Reality (AR), and Artificial Intelligence (AI). h2O intends to make real-time human data become a handy tool for disease management in certain therapeutic areas. Their core understanding of digital therapeutics lies in the power of AI, the robustness of their clinical health research, and high levels of user engagement.
Contact Information:
Yagmur Selin Gulmus
Founder
Hande Erciyes
Operations Manager
Press Release Service
by
Newswire.com
Original Source:
H2o Therapeutics Gets FDA Clearance for Its Apple Watch-Based App for Parkinson’s Disease
Employees allege firing after religious exemptions to covid shot mandate were denied
BOSTON – Nove…
Altrua Ministries in Action
Altrua HealthShare + Jordan Feliz + Danny Gokey + Convoy of Hope Donation Presentation of check Danny Gokey and Jorda…
Altrua Ministries in Action
Altrua HealthShare + Jordan Feliz + Danny Gokey + Convoy of Hope Donation Presentation of check Danny Gokey and Jorda…
Massive Bio, which uses artificial intelligence to match cancer patients to clinical trials, launches “I Have Cancer,” a social media campaign to raise cancer awareness.
NEW YORK – November 17, 2022 – (Newswire.com)
In keeping with its mission to improve the lives of cancer patients, Massive Bio aims to raise mass awareness about cancer, cancer treatments, and clinical research with “I Have Cancer,” the company’s new social media campaign. “I Have Cancer” will focus on the problems experienced by cancer patients and their loved ones while bringing attention to the importance of cancer prevention. The campaign will also provide up-to-date information about oncology clinical trials for cancer patients interested in pursuing innovative new treatments. Massive Bio, based in New York City, uses a proprietary artificial intelligence platform called SYNERGY-AI to match cancer patients to clinical trials.
“This project is very important for society,” says Erkan Terzi, Global Marketing Vice President for Massive Bio and one of the architects of the “I Have Cancer” campaign. “We have cancer awareness, but the problem is how much we understand cancer and cancer patients. Millions of people die from cancer yearly, and everyone is at risk of getting cancer. With this project, we want to raise cancer awareness, show how we can protect ourselves and our loved ones, and provide information about cancer treatments.”
“Clinical milestones include working with physicians, pharmaceutical and genomic testing providers, and hospitals, as well as our network of oncology clinical trial registration opportunities in Europe and South America,” said Çağatay Çulcuoğlu, co-founder, CFO, and COO of Massive Bio. “We have expanded our patient-engagement activities through advocacy groups, webinars, and the publication of Massive Bio magazine, which informs readers about the latest news in cancer research and clinical trials. Now, with our ‘I Have Cancer’ campaign, we aim to be the voice of patients and their families who need support and are not heard but who want to share their experiences and ideas to build a better tomorrow for future generations.”
The “I Have Cancer” campaign, which will launch in November with posts on Massive Bio’s social media channels, will emphasize the theme that cancer patients are not alone. The importance of cancer foundations and associations will also be highlighted in the campaign, carried out simultaneously on Facebook, Instagram, TikTok, Twitter, LinkedIn, and YouTube. The campaign will use the hashtags #ihavecancer, #cancerawareness, and #massivebio to help cancer patients and their supporters make their voices heard. The campaign will continue until the end of May.
About Massive Bio
Massive Bio’s mission is to provide access to clinical trials for cancer patients worldwide, regardless of where they live or their financial circumstances. Massive Bio solves bottlenecks in recruiting patients for clinical trials with a unique technology-enabled service and big data platform. The company serves pharmaceutical companies, contract research organizations, and hospital networks with a focus on improving the lives of cancer patients and provides oncology-specific data-driven patient recruitment, site selection, and AI-based trial pre-screening services.
Contact Information:
merve sahin
PR Executive
+1 844 627 7246
Press Release Service
by
Newswire.com
Original Source:
Massive Bio Launches ‘I Have Cancer’ Campaign
Massive Bio, which uses artificial intelligence to match cancer patients to clinical trials, launches “I Have Cancer,” a social media campaign to raise cancer awareness.
NEW YORK – November 17, 2022 – (Newswire.com)
In keeping with its mission to improve the lives of cancer patients, Massive Bio aims to raise mass awareness about cancer, cancer treatments, and clinical research with “I Have Cancer,” the company’s new social media campaign. “I Have Cancer” will focus on the problems experienced by cancer patients and their loved ones while bringing attention to the importance of cancer prevention. The campaign will also provide up-to-date information about oncology clinical trials for cancer patients interested in pursuing innovative new treatments. Massive Bio, based in New York City, uses a proprietary artificial intelligence platform called SYNERGY-AI to match cancer patients to clinical trials.
“This project is very important for society,” says Erkan Terzi, Global Marketing Vice President for Massive Bio and one of the architects of the “I Have Cancer” campaign. “We have cancer awareness, but the problem is how much we understand cancer and cancer patients. Millions of people die from cancer yearly, and everyone is at risk of getting cancer. With this project, we want to raise cancer awareness, show how we can protect ourselves and our loved ones, and provide information about cancer treatments.”
“Clinical milestones include working with physicians, pharmaceutical and genomic testing providers, and hospitals, as well as our network of oncology clinical trial registration opportunities in Europe and South America,” said Çağatay Çulcuoğlu, co-founder, CFO, and COO of Massive Bio. “We have expanded our patient-engagement activities through advocacy groups, webinars, and the publication of Massive Bio magazine, which informs readers about the latest news in cancer research and clinical trials. Now, with our ‘I Have Cancer’ campaign, we aim to be the voice of patients and their families who need support and are not heard but who want to share their experiences and ideas to build a better tomorrow for future generations.”
The “I Have Cancer” campaign, which will launch in November with posts on Massive Bio’s social media channels, will emphasize the theme that cancer patients are not alone. The importance of cancer foundations and associations will also be highlighted in the campaign, carried out simultaneously on Facebook, Instagram, TikTok, Twitter, LinkedIn, and YouTube. The campaign will use the hashtags #ihavecancer, #cancerawareness, and #massivebio to help cancer patients and their supporters make their voices heard. The campaign will continue until the end of May.
About Massive Bio
Massive Bio’s mission is to provide access to clinical trials for cancer patients worldwide, regardless of where they live or their financial circumstances. Massive Bio solves bottlenecks in recruiting patients for clinical trials with a unique technology-enabled service and big data platform. The company serves pharmaceutical companies, contract research organizations, and hospital networks with a focus on improving the lives of cancer patients and provides oncology-specific data-driven patient recruitment, site selection, and AI-based trial pre-screening services.
Contact Information:
merve sahin
PR Executive
+1 844 627 7246
Press Release Service
by
Newswire.com
Original Source:
Massive Bio Launches ‘I Have Cancer’ Campaign
U.S. hospitals and healthcare systems gain access to expanded toolset for driving compliance to CMS & OIG regulations.
SpendMend SpendMend
…
